Arvinas (NASDAQ:ARVN – Get Rating) had its price target reduced by analysts at Barclays from $90.00 to $70.00 in a research note issued on Wednesday, The Fly reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 76.95% from the stock’s previous close.
A number of other research analysts have also recently commented on ARVN. HC Wainwright cut their price target on shares of Arvinas from $135.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, August 5th. Capital One Financial began coverage on shares of Arvinas in a research note on Tuesday, October 25th. They issued an “overweight” rating for the company. SVB Leerink lowered their price objective on shares of Arvinas from $89.00 to $74.00 and set an “outperform” rating for the company in a research note on Tuesday. Morgan Stanley lowered their price objective on shares of Arvinas from $63.00 to $57.00 and set an “equal weight” rating for the company in a research note on Friday, November 11th. Finally, Credit Suisse Group upped their price objective on shares of Arvinas to $81.00 in a research note on Tuesday, November 15th. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Arvinas has a consensus rating of “Moderate Buy” and a consensus price target of $79.19.
Arvinas Trading Down 2.8 %
NASDAQ ARVN opened at $39.56 on Wednesday. The company’s 50-day moving average price is $45.35 and its 200-day moving average price is $45.79. The stock has a market cap of $2.11 billion, a PE ratio of -8.31 and a beta of 1.89. Arvinas has a 12 month low of $34.90 and a 12 month high of $83.40.
Institutional Trading of Arvinas
Hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its position in shares of Arvinas by 37.6% during the third quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock valued at $54,000 after buying an additional 336 shares during the last quarter. SeaCrest Wealth Management LLC purchased a new position in shares of Arvinas in the 2nd quarter valued at approximately $57,000. Lazard Asset Management LLC purchased a new position in shares of Arvinas in the 1st quarter valued at approximately $57,000. Amundi purchased a new position in shares of Arvinas in the 2nd quarter valued at approximately $62,000. Finally, Federated Hermes Inc. raised its position in shares of Arvinas by 80,650.0% in the 2nd quarter. Federated Hermes Inc. now owns 1,615 shares of the company’s stock valued at $68,000 after purchasing an additional 1,613 shares during the last quarter. 91.20% of the stock is owned by hedge funds and other institutional investors.
Arvinas Company Profile
Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
- Get a free copy of the StockNews.com research report on Arvinas (ARVN)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.